Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.81

1.165 (2.17%)

16:22
06/17/18
06/17
16:22
06/17/18
16:22

Bristol-Myers' ELOQUENT-3 trial meets primary endpoint

Bristol-Myers Squibb announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for patients treated with EPd compared with pomalidomide and dexamethasone alone. ELOQUENT-3 is the only randomized, active-controlled trial to investigate a pomalidomide-based triplet combination in patients with RRMM who received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Twice as many patients randomized to EPd responded to therapy compared to patients randomized to Pd alone. Patients randomized to EPd demonstrated an overall response rate of 53%, compared with 26% among patients randomized to Pd. Time to first response was comparable for patients receiving EPd and Pd at 1.95 and 1.91 months, respectively. Median duration of response had not been reached among patients randomized to EPd at time of analysis. Overall survival, a secondary endpoint, although not mature at this time, showed a positive trend favoring EPd over Pd alone. Treatment-related Grade 3-4 adverse events were comparable between EPd and Pd groups.

  • 26

    Jun

  • 10

    Jul

BMY Bristol-Myers
$54.81

1.165 (2.17%)

05/21/18
UBSW
05/21/18
DOWNGRADE
Target $57
UBSW
Neutral
Bristol-Myers downgraded to Neutral from Buy at UBS
UBS analyst Marc Goodman downgraded Bristol-Myers to Neutral from Buy. Goodman lowered his price target to $57 from $67 on Bristol-Myers shares.
05/21/18
05/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Buy at UBS. 2. Campbell Soup (CPB) downgraded to Underperform from Neutral at BofA/Merrill with analyst Bryan Spillane saying he expects 2019 to be a transition year and for operating profits and earnings to decline modestly. 3. American Eagle (AEO) downgraded to Hold from Buy at SunTrust with analyst Pamela Quintilliano saying the fundamentals are not catching up to the continued advance in the stock price. 4. Andeavor Logistics (ANDX) downgraded to Neutral from Overweight at JPMorgan with analyst Jeremy Tonet citing the new drop outlook following the parent merger announcement as well as lower than expected Q1 estimates. 5. Williams Partners (WPZ) downgraded to Hold from Buy at Stifel and to Outperform from Strong Buy at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

NCLH

Norwegian Cruise Line

$50.01

2.43 (5.11%)

15:40
07/18/18
07/18
15:40
07/18/18
15:40
Options
Norwegian Cruise Lines options volume is 27X daily average as shares rally »

Norwegian Cruise Lines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$17.77

0.08 (0.45%)

15:34
07/18/18
07/18
15:34
07/18/18
15:34
Options
Kinder Morgan options imply 4.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MDR

McDermott

$17.99

-0.05 (-0.28%)

15:30
07/18/18
07/18
15:30
07/18/18
15:30
Options
McDermott option volume is 6X daily average and puts lead calls 30:1 »

McDermott option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

OMC

Omnicom

$70.32

-0.37 (-0.52%)

15:20
07/18/18
07/18
15:20
07/18/18
15:20
Options
Heavy Omnicom option volume likely adjusts open positions »

Heavy Omnicom option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AXP

American Express

$102.70

1.56 (1.54%)

15:19
07/18/18
07/18
15:19
07/18/18
15:19
Options
American Express options imply 5.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

BPL

Buckeye Partners

$33.37

-1.58 (-4.52%)

15:17
07/18/18
07/18
15:17
07/18/18
15:17
Hot Stocks
Moody's changes Buckeye Partners' outlook to negative from stable »

Moody's Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
07/18/18
07/18
15:17
07/18/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
07/18/18
07/18
15:16
07/18/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$50.98

-0.56 (-1.09%)

, WEN

Wendy's

$17.53

0.105 (0.60%)

15:13
07/18/18
07/18
15:13
07/18/18
15:13
Periodicals
Papa John's founder held merger discussions with Wendy's, WSJ reports »

Papa John's…

PZZA

Papa John's

$50.98

-0.56 (-1.09%)

WEN

Wendy's

$17.53

0.105 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

  • 15

    Aug

CCK

Crown Holdings

$45.16

-0.22 (-0.48%)

15:10
07/18/18
07/18
15:10
07/18/18
15:10
Options
Third day of call buying in Crown Holdings ahead of earnings »

Third day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

BIIB

Biogen

$356.40

1.46 (0.41%)

15:06
07/18/18
07/18
15:06
07/18/18
15:06
Periodicals
Biogen presented as best idea by Alex Denner, CNBC says »

Alex Denner of Sarissa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 31

    Jul

PZZA

Papa John's

$51.02

-0.52 (-1.01%)

, WEN

Wendy's

$17.52

0.1 (0.57%)

15:05
07/18/18
07/18
15:05
07/18/18
15:05
Periodicals
Breaking Periodicals news story on Papa John's, Wendy's »

Papa John's founder…

PZZA

Papa John's

$51.02

-0.52 (-1.01%)

WEN

Wendy's

$17.52

0.1 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

  • 15

    Aug

IBM

IBM

$144.11

0.65 (0.45%)

, GRPN

Groupon

$4.70

0.07 (1.51%)

15:04
07/18/18
07/18
15:04
07/18/18
15:04
Earnings
On The Fly: What to watch for in IBM's earnings report »

IBM (IBM) is scheduled to…

IBM

IBM

$144.11

0.65 (0.45%)

GRPN

Groupon

$4.70

0.07 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

EBAY

eBay

$38.08

0.26 (0.69%)

15:04
07/18/18
07/18
15:04
07/18/18
15:04
Options
EBay options imply 10.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

15:00
07/18/18
07/18
15:00
07/18/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ABUS

Arbutus Biopharma

$11.30

-0.05 (-0.44%)

14:58
07/18/18
07/18
14:58
07/18/18
14:58
Conference/Events
Arbutus Biopharma management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

MSEX

Middlesex Water

$44.59

-0.04 (-0.09%)

14:56
07/18/18
07/18
14:56
07/18/18
14:56
Hot Stocks
Middlesex Water unit awarded City of Perth Amboy contract »

Utility Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$51.48

1.51 (3.02%)

14:53
07/18/18
07/18
14:53
07/18/18
14:53
Hot Stocks
Phillips 66 Partners announces 5.3% increase in quarterly distribution »

Phillips 66 Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

TTWO

Take-Two

$126.13

-0.6 (-0.47%)

14:50
07/18/18
07/18
14:50
07/18/18
14:50
Periodicals
Greenberg presents Take-Two as best idea at 'Delivering Alpha' »

Samantha Greenberg,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 06

    Sep

GOGO

Gogo

$3.96

0.2 (5.32%)

14:50
07/18/18
07/18
14:50
07/18/18
14:50
Options
Rebound in shares of GOGO Wireless draws opening put seller »

Rebound in shares of GOGO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$143.99

0.53 (0.37%)

14:49
07/18/18
07/18
14:49
07/18/18
14:49
Options
IBM options imply 6.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

OMED

OncoMed

$2.40

0.04 (1.69%)

14:48
07/18/18
07/18
14:48
07/18/18
14:48
Conference/Events
OncoMed management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GOOG

Alphabet

$1,200.98

2.17 (0.18%)

, GOOGL

Alphabet Class A

$1,217.97

4.32 (0.36%)

14:42
07/18/18
07/18
14:42
07/18/18
14:42
Periodicals
FTC chairman to look 'closely' at EU's move to fine Google, Reuters says »

U.S. Federal Trade…

GOOG

Alphabet

$1,200.98

2.17 (0.18%)

GOOGL

Alphabet Class A

$1,217.97

4.32 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

PHM

PulteGroup

$30.91

-0.02 (-0.06%)

, DHI

D.R. Horton

$43.21

-0.02 (-0.05%)

14:42
07/18/18
07/18
14:42
07/18/18
14:42
Hot Stocks
Homebuilders fall as housing starts crevice to nine-month low »

Shares of U.S. home…

PHM

PulteGroup

$30.91

-0.02 (-0.06%)

DHI

D.R. Horton

$43.21

-0.02 (-0.05%)

LEN

Lennar

$54.96

-0.59 (-1.06%)

KBH

KB Home

$27.02

-0.46 (-1.67%)

MTH

Meritage Homes

$46.05

-0.9 (-1.92%)

BZH

Beazer Homes

$15.51

-0.13 (-0.83%)

TOL

Toll Brothers

$37.73

-0.31 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

ADTN

Adtran

$16.05

(0.00%)

, CTL

CenturyLink

$19.54

-0.085 (-0.43%)

14:34
07/18/18
07/18
14:34
07/18/18
14:34
Downgrade
Adtran, CenturyLink rating change  »

Adtran downgraded to…

ADTN

Adtran

$16.05

(0.00%)

CTL

CenturyLink

$19.54

-0.085 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.